Based on extensive research supported by NIH/NINDS and performed under Dr. Carleton Hsia as principal investigator, the FDA has concurred that continued development for critical care and transfusion medicine is justified of the company's multifunctional nano red blood cell (nRBC) (aka, polynitroxylated peglylated hemoglobin, PNPH or VitalHemeTM). A US Patent for nRBC was granted in September of 2012 and is assigned to NanoBlood LLC (
Click here for our US patent), and nRBC may be an ideal opportunity for a Big Pharma company to add to their pipeline.
Click here for our US patent), and nRBC may be an ideal opportunity for a Big Pharma company to add to their pipeline. NanoBlood LLC is now seeking to enter into global and regional licensing to develop and commercialize nRBC as a bridge and alternative to red blood cell transfusion as well as a life saving nano medicine to meet unmet critical care medical needs where there is inadequate blood flow and oxygen delivery, specifically in hemorrhagic shock, traumatic brain injury complicated by hemorrhagic shock, stroke, and sickle cell disease.
NanoBlood is an affiliate of AntiRadical Therapeutics LLC (www.antiradicaltherapeutics.com).